IDO1 and sarcoma: Results as presented in Figure 3D.4 revealed increment in such ratio, favoring the T cell mediated anti-tumor immunity. Other regulatory molecules, such as IL-10, TGFβ, IDO, were also downregulated in tumors of NLGP-treated sarcoma mice (data not shown).